In Vitro Studies Find New AIDS Drug Effective

laboratories have returned preliminary data showing that the drug RPI-MN is effective against the AIDS virus.

The biotechnology holding company Nutra Pharma Corp. (Boynton Beach, FL, USA) recently announced that its minority-owned subsidiary ReceptoPharm Inc. (Fort Lauderdale, FL, USA) had received results from two independent clinical studies that showed that the drug RPI-MN was an effective blocker of the two most important HIV isolates involved in primary infection of the host and the destruction of T cells. The tests were conducted in laboratories at Northwestern University (Chicago, IL, USA) and the University of California, San Diego (USA).

ReceptoPharm is now continuing laboratory studies to discover whether RPI-MN has any special attributes that would support an accelerated entry into clinical trials for the treatment of HIV and AIDS. The company is developing proprietary therapeutic proteins for the treatment of chronic, life-threatening viral, autoimmune and neurodegenerative disorders.

"We now have solid evidence that ReceptoPharm's lead drug should be effective in HIV patients,” said Dr. Rik Deitsch, CEO of Nutra Pharma. "ReceptoPharm will now focus on moving the drug through controlled human trials.”

Dr. Paul F. Reid, CEO of ReceptoPharm, said, "We have been very satisfied with the synergies we have found between our two companies that we hope will now lead to the rapid initiation of clinical studies in several diseases that are currently without satisfactory treatment options.”




Related Links:
Nutra Pharma